Efficacy and Renal Safety of Dapagliflozin in Patients with Type 2 Diabetes Mellitus Also Receiving Metformin: A Real-Life Experience

Table 2

Secondary efficacy and safety parameters.

	DAPA + MET alone ()		DAPA + MET + other glucose-lowering drugs ()^a
	Baseline	12 months	Baseline	12 months
BMI (kg/m^2)
Mean ± SD	33.1 ± 6.2	32.5 ± 6.0	33.8 ± 6.3	32.9 ± 5.2
Δ	−0.7 (−1.1 to −0.3)		−0.9 (−1.3 to −0.5)
Value	<0.001		0.009
Total cholesterol (mg/dL)
Mean ± SD	189.5 ± 33.9	184.1 ± 40.1	183.8 ± 42.2	177.9 ± 32.1
Δ	−2.2 (−15.8 to +11.4)		−10.9 (−25.2 to +3.4)
LDL cholesterol (mg/dL)
Mean ± SD	111.1 ± 32.2	104.9 ± 36.4	108.1 ± 38.2	103.6 ± 31.6
Δ	−4.8 (−17.0 to +7.4)		−9.5 (−22.4 to +3.3)
HDL cholesterol (mg/dL)
Mean ± SD	47.7 ± 11.9	52.2 ± 13.0	48.5 ± 11.8	48.3 ± 10.6
Δ	+4.8 (+0.6 to +9.1)		+0.8 (−3.8 to +5.3)
Triglycerides (mg/dL)
Mean ± SD	145.8 ± 62.9	135.1 ± 54.2	134.8 ± 61.2	129.7 ± 57.2
Δ	−4.5 (−24.6 to +15.6)		−5.8 (−27.0 to +15.5)
Microalbumin (μg/mg)
Mean ± SD	119.5 ± 139.6	93.6 ± 103.2	67.1 ± 80.6	54.0 ± 52.3
Δ	−22.9 (−30.6 to −15.2)		−18.6 (−27.1 to −10.0)
Value	0.002		0.070

Δ = mean (95% confidence interval) change from baseline to 12 months. BMI, body mass index; DAPA, dapagliflozin; HDL, high density lipoprotein; LDL, low density lipoprotein; MET, metformin; SD, standard deviation. ^aAdditional glucose-lowering agents included glimepiride or insulin. and .